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Abstract
The successful use of specialized cells in regenerative medicine requires an optimization in
the differentiation protocols that are currently used. Understanding the molecular events
that take place during the differentiation of human pluripotent cells is essential for the
improvement of these protocols and the generation of high quality differentiated cells. In an
effort to understand the molecular mechanisms that govern differentiation we identify the
methyltransferase SETD7 as highly induced during the differentiation of human embryonic
stem cells and differentially expressed between induced pluripotent cells and somatic cells.
Knock-down of SETD7 causes differentiation defects in human embryonic stem cell
including delay in both the silencing of pluripotency-related genes and the induction of differ-
entiation genes. We show that SETD7 methylates linker histone H1 in vitro causing confor-
mational changes in H1. These effects correlate with a decrease in the recruitment of H1 to
the pluripotency genes OCT4 and NANOG during differentiation in the SETD7 knock down
that might affect the proper silencing of these genes during differentiation.
Introduction
The generation of specialized cell types from human pluripotent cells in the laboratory can pro-
vide an unlimited source of cells and tissues useful for transplantation and therefore holds a
great promise for regenerative medicine (Reviewed in [1]). Successful therapies depend on the
generation of functional cell types that have enough plasticity to survive and repopulate the
damaged tissues with a low risk of forming tumors [2]. In order to achieve these goals the cur-
rent protocols used to differentiate cells will need to be improved and the quality of the differ-
entiated products more strictly evaluated. A recent study comparing the similarity of in vitro
and in vivo differentiated cells highlights the existence of significant differences both at the
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level of gene expression and chromatin marks [3], confirming that improved in vitro differenti-
ation methods are needed to obtain cells similar to their in vivo counterparts. Therefore, under-
standing the molecular mechanisms that take place during differentiation appears essential for
the development of optimal differentiation protocols.
Important advancements in the stem cell field include the generation of human induced
pluripotent stem cells (iPSCs) from somatic cells [4] which show similar properties to human
embryonic stem cells (ESCs). While iPSCs cells can provide an invaluable source of cells for
autologous transplantation, their safety for use in the clinic is still unclear [5]. In order to assess
the potential risks of using reprogrammed cells for therapy a closer look at the mechanisms of
reprogramming and their consequences is warranted.
In an effort to identify critical factors involved in determining cell identity we previously
compared the expression patterns of pluripotent and somatic cells [6]. We described a network
of factors that are predominantly expressed in pluripotent human cells, encompassing factors
that had been previously used to reprogram cells such as OCT4, SOX2, NANOG, LIN28 or
SALL4, components of signal transduction pathways such as TGDF1, FGFR2, FGFR3 and
NODAL, and the chromatin-related proteins PRDM14, TET1, JARID2, DNMTs and CBX2.
Importantly, we also identified a network of genes that were preferentially expressed in differ-
entiated cells, including the histone variant H2AFY that plays critical roles in preserving the
identity of somatic cells [7,8].
Among the factors that we found upregulated in somatic cells compared to pluripotent cells
we noticed the protein lysine methyltransferase SETD7 (also called SET7/9 or KMT7). SETD7
was initially described as a histone methyltransferase able to mediate the monomethylation of
histone H3 at lysine 4 (H3K4me1) in vitro [9]. However, the fact that it cannot efficiently
methylate nucleosomal substrates [9,10] suggests that its physiological substrate in vivo might
be different than histone H3. Accordingly, numerous non-histone targets have been described
for SETD7, including p53 [11], ERα [12], p65 [13], STAT3 [14], pRB [15], SIRT1[16], DNMT1
[17], FOXO3 [18], SUV39H1 [19], E2F1 [20], AR [21], FXR [22], PCAF [23], PARP1 [24] and
TAF10 [25] that are potential mediators of SETD7 effects.
Here, we have confirmed that SETD7 is expressed at very low levels in human pluripotent
cells and strongly induced during differentiation. We have identified novel SETD7 interaction
partners in differentiated cells. Among these partners we describe that linker histone H1 is
methylated by SETD7. This methylation is likely to lead to structural changes that modulate
the affinity of histone H1 for chromatin during human pluripotent cells differentiation contrib-
uting to orchestrate the changes in gene expression that take place during this process.
Materials and Methods
Cell culture
Human embryonic stem cell lines used in this study were previously published; ES[4] and ES
[2] (described in [26]) and KiPSCs (described in [27]). For viral infection cells were grown in
matrigel coated plates, in the presence of irradiated MEF’s conditioned HES media (Knock Out
DMEM supplemented with 20% KO serum replacement, 1X MEM non essential amino acids,
2mM L-glutamine and 50μM β-mercaptoethanol) supplemented with 10ng/ml FGF and sub-
cultured as aggregates using trypsin.
For differentiation studies using the SETD7 inhibitor pluripotent cells were cultured in
matrigel coated plated using mTeSR1 media (STEMCELL Technologies) and subcultured as
aggregates using dispase. Keratinocytes and fibroblasts were cultured as previously described
[28].
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Lentiviral vectors and viral production
pLKO.1-puro lentiviral vectors containing different shRNAs against human SETD7 were pur-
chased from SIGMA TRCN0000078628 (sh28), TRCN0000078629 (sh29), TRCN0000078630
(sh30), TRCN0000078631 (sh31), TRCN0000078632 (sh32). Viruses were produced as previ-
ously described [29]. For FLAG tagged SETD7 over expression we used the lentiviral vector
pWPI (http://tronolab.epfl.ch) (Addgene plasmid 12254).
In vitro differentiation of pluripotent cells
Lentiviral infected cells were trypsinized into a single cell suspension and resuspended in
MEF’s conditioned HES media. Embryoid body (EB) formation was induced by seeding
100,000 cells in each well of 96-well v-bottom, low attachment plates and centrifuging the
plates at 950g for 5 min to aggregate the cells. After 3 days the embryoid bodies were trans-
ferred to 0.1% gelatin-coated dishes and cultured in differentiation medium (Knock out
DMEM supplemented with 20% fetal bovine serum, 1X MEM non essential amino acids, 2mM
L-glutamine and 50μM β-mercaptoethanol) up to 20 days. The medium was changed every
four days.
For the SETD7 inhibitor PFI-2 treatment cells were maintained in mTeSR1 media, detached
using dispase and cultured in suspension as agregates in low attachment plates for 48 hours.
Then the formed embryoid bodies were transferred to 0.1% gelatin-coated slide flasks and cul-
tured in differentiation medium (Knock out DMEM supplemented with 20% fetal bovine
serum, 1X MEM non essential amino acids, 2mM L-glutamine and 50μM β-mercaptoethanol)
and presence of vehicle (DMSO) or PFI-2 up to 7 days. The medium was changed every four
days.
Real time PCR and microarray analysis
Total RNA was isolated using TRIZOL and 1 μg was used to synthesize cDNA using the Invi-
trogen Cloned AMV First-Strand cDNA synthesis kit. One μl of the reaction was used to quan-
tify gene expression by qPCR. Oligonucleotides for amplification of endogenous pluripotency
factors and differentiation genes were previously described [27]. Oligonucleotides for p21 and
SETD7 amplification were the following (F, forward; R, reverse): SETD7.F 5’TTCACTCCAA
ACTGCATCTACGA3’; SETD7.R 5’GCATTTGATGGGCCCAAA3’; P21.F 5’TGGAGACTC
TCAGGGTCGAAA3’; P21.R 5’GCGTTTGGAGTGGTAGAAATCTG3’.
For microarray analysis total RNA was isolated using the RNAeasy kit from Qiagen and
analyzed using the Affymetrix Human U133 2.0 Plus array. The GeneChip microarray process-
ing was performed by the Functional Genomics Core in the Institute for Research in Biomedi-
cine (Barcelona, Spain) according to the manufacturer's protocols (Affymetrix) as described
previously [30]. The amplification and labeling were processed as indicated in the Nugen pro-
tocol with 25 ng starting RNA. For each sample, 3.75 mg single-stranded DNA was labeled and
hybridized to the chips. Expression signals were scanned on an Affymetrix GeneChip Scanner
(7G upgrade). The data extraction was done by the Affymetrix GCOS software v.1.4. Raw data
were normalized using the gcRMA algorithm implemented in R. Heatmaps were generated
using GENE-E (http://www.broadinstitute.org/cancer/software/GENE-E) and box plots using
BoxPlotR (http://boxplot.tyerslab.com/).
For GSEAPreranked [31] genes were pre-ranked according to fold change for each treat-
ment obtained in the RNA-seq analysis, setting ‘gene set’ as the permutation method and with
1000 permutations.
Data has been deposited at GEO under accession number GSE24768.
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Western blot analysis
Whole cell extracts were isolated using RIPA buffer and 30 μg protein was analyzed by western
blot using specific antibodies against OCT4 (Santa Cruz sc-5279), SOX2 (Neuromics
GT15098), α-1-Fetoprotein (AFP; Dako, A0008), SETD7 (Millipore 07–314), TUBA (Santa
Cruz sc-135592), ACTB (Sigma AV40173) or FLAG (Sigma M2).
Cell Cycle Analyses
Cell cycle analyses were performed using Click-iT1 EdU Alexa Fluor1 488 Flow Cytometry
Assay Kit (Invitrogen) according to manufacturer instructions.
Immunofluorescence
Cells were grown on plastic cover slide chambers and fixed with 4% paraformaldehyde at room
temperature for 20 min. The immunodetection was performed with TBS-0.2%triton X-100 for
permeabilization, primary antibodies were incubated at 4°C overnight and secondary antibod-
ies at 37°C for 2h. Antibodies used were OCT4 (sc-5279 from Santa Cruz) and SOX2 (PA1-
16968 from ABR). Secondary antibodies used were all cyanine conjugated from Jackson (all
1:400). Images were taken using Leica SP5 AOBS confocal microscope.
Chromatin immunoprecipitation
The chromatin immunoprecipitation (ChIP) assays were performed according to the Millipore
protocol. Briefly, 1 million human ESCs were used for each immunoprecipitation. Cells were
fixed using 1% formaldehyde, harvested, resuspended in ChIP lysis buffer (1% SDS, 10mM
EDTA, 50mM Tris-HCl, pH 8.1) and sonicated using the Branson Digital Sonifier to generate
fragments of 150 to 500 bp. Soluble chromatin was diluted 8 fold in ChIP RIPA buffer (10 mM
Tris–HCl, pH 7.5, 140 mMNaCl, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% SDS,
0.1% Na-deoxycholate) and incubated with Dynabeads Protein A (Invitrogen) coupled to nor-
mal rabbit IgG or specific antibodies fromMillipore against H3K4me2 (07–030), H3K27me3
(07–449) or H1 (clone AE-4). After incubation, the immunocomplexes were washed sequen-
tially with Low Salt Wash Buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl,
pH 8.1, 150mMNaCl), High Salt Wash Buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA,
20mM Tris-HCl, pH 8.1, 500mMNaCl), LiCl Wash Buffer (0.25M LiCl, 1% NP40, 1% deoxy-
cholate, 1mM EDTA, 10mM Tris-HCl, pH 8.1) and TE. Immunocomplexes were eluted in
ChIP elution buffer (1%SDS, 0.1M NaHCO3) and the crosslinking was reverted overnight at
65°C. Samples were treated with Proteinase K and RNase A and DNA was extracted using the
Qiagen PCR purification kit. Purified chromatin was quantified using qPCR and the following
oligonucleotides (F, forward; R, reverse): SETD7Pro.F 5’ ACCGGCGCTGGGTGAT3’; SETD7-
Pro.R 5’CCTGTAATACCCTCTCTTTGTTATCGA3’. Oligonucleotides for amplification of
OCT4, NANOG and GAPDH regulatory regions were previously reported [8].
Identification of SETD7 interacting proteins
Nuclear extract from 400x106 HeLa cells transduced with empty vector or with FLAG:SETD7
overexpressing vector was prepared as previously described [32]. Extract were adjusted to 300
mM salt and 0.1% NP40 and incubated with ANTI-FLAGM2 affinity gel (Sigma). Beads were
extensively washed with BC300 (20 mM TrisCl, pH 7.5, 20% glycerol, 0.2 mM EDTA and 300
mM KCl) containing 0.1% NP40. Proteins were eluted using 0.3 mg/ml of FLAG peptide, pre-
cipitated using trichloroacetic acid and resolved on SDS-PAGE gels or directly processed for
mass spectrometry. Two independent immunoprecipitations were used for each method.
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In vitro methylation assays
H1 variants constructs were generated by PCR amplification from lentiviral expression vectors
[33] and cloned into 6His-pET11d. Mutations were introduced by overlap extension. Expres-
sion plasmid for His-tagged SETD7 was previously described [34]. His-tagged proteins were
expressed in E.coli and purified over Ni-NTA agarose. Calf thymus H1 was purchased from
Santa Cruz Biotechnology. For expression of GST-H3 tail the H3 tail (residues 1–41) was
cloned into the vector pGEX4T2 and purified using glutathione-Sepharose. Recombinant H3
was expressed in E.coli and purified as previously described [35]. Purified PRMT1 was a gift
from S. Malik [36].
In vitromethylation assays were performed in a total volume of 20 μl containing 50 mM
Tris-HCl (pH 9.0), 1 mM phenylmethylsulfonyl fluoride (PMSF), 0.5 mM dithiothreitol
(DTT), 1 μl [3H]SAM (15 Ci/mmol; PerkinElmer), 2 μg of substrate and 200 ng of enzyme at
30°C for 2 hours. Products were resolved by SDS-PAGE, stained with Coomassie and analyzed
by fluorography. Alternatively, 20μM SAM (SIGMA) was used and samples subjected to mass
spectrometry.
Mass spectrometry analysis of methylated H1
After in vitro methylation, sample was subjected to chromatography on a BioSuite pPhenyl
1000 column (Waters) (10 μm RPC, 4.6 × 75 mm), using a linear gradient of 5% to 80% B in 60
min (A = 0.1% FA in H2O, B = 0.1% FA in CH3CN) at a flow rate of 1 ml/min. The LC eluent
was coupled to a LCT-Premier XE mass spectrometer (Waters-Microness) provided with an
ESI source. Data was acquired with MassLynx software, V4.1. SCN639 (Waters Inc.). Charged
species were deconvoluted to zero charged average mass with MaxEnt 1 algorithm (Waters
Inc.)
Infrared spectroscopy
FTIR spectra of unmethylated and methylated human histone H1.4 were measured at 5 mg/ml
in 10 mMHEPES, pH 7.0 plus 140 mMNaCl in D2O medium. Measurements were performed
on a FT600 Bio-Rad spectrometer equipped with a MCT detector, using a demountable liquid
cell with calcium fluoride windows and 50 μm spacers. Typically, 1000 scans for each back-
ground and sample were collected and the spectra were obtained with a nominal resolution of
2 cm-1, at 22°C. DNA-protein complexes contained the appropriate amount of DNA for each
protein/DNA ratio (w/w). The DNA contribution to the spectra of the complexes with the
H1.4 species was subtracted as described [37]. Data treatment and band decomposition of the
original amide I’ band was performed as previously described [38] using GRAMS 9.0 software.
In vivo methylation of Histone extracts
HeLa cells were incubated in growth medium Dulbecco’s Modified Eagle’s Medium (DMEM),
10% Fetal Bovine Serum (FBS), 100 μg/ml cycloheximide, 40 μg/ml chloroamphenicol and
50 μl of L-[methyl-3H] methionine (1mCi/ml) for 3 hours at 37°C. After that the histone frac-
tion was isolated by acid extraction and resolved by SDS-PAGE. Proteins were visualized by
Coomassie blue staining, followed by autoradiography.
Source of public data
Public data in the human embryonic cell line H1 was generated by the ENCODE project [39].
Data on H3K27me3 (GSM733748), H3K4me2 (GSM733670) and H3K4me3 (GSM733657)
was generated at the Bernstein laboratory (Broad Institute). Data on Pol II occupancy
SETD7 Regulates Differentiation
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(GSM822300) was generated at the Iyer laboratory (University of Texas at Austin). Data on
DNAmethylation (GSM683770) was generated at the Myers laboratory (Hudson Alpha Insti-
tute for Biotechnology). Data was displayed in the UCSC Genome Browser.
Statistical methods
Benjamini P-values for gene ontology functional annotation were obtained using the DAVID
analysis tool (http://david.abcc.ncifcrf.gov/). The significance of the differences in cell cycle dis-
tribution, H1 occupancy and gene expression at different days of differentiation were analyzed
using the Student’s t test.
Ethical statement
This study was done in accordance with Spanish laws and regulations regarding the manipula-
tion of human pluripotent cells and approved by the Spanish competent authorities (Comisión
de Seguimiento y Control de la Donación de Células y Tejidos Humanos del Instituto de Salud
Carlos III).
Results
SETD7 is preferentially expressed in differentiated cells
In order to identity factors that play critical roles in the regulation of cell identity, we previously
compiled publically available genome-wide expression data from 15 human iPSC lines and
their fibroblasts of origin, and 12 human ESC lines [6]. For each set of data candidates were
ranked according to their differential expression between pluripotent and somatic cells and top
1000 ranked genes were selected based on the average rank from all comparisons [6]. The top
ranked differentially expressed genes in both iPSCs and ESCs compared to fibroblasts are
shown in Fig 1A (See also S1 Table). As expected, pluripotency-related factors like OCT4,
SOX2 and NANOG as well as previously reported chromatin-related factors DNMT3B and
JARID2 were highly ranked as upregulated in pluripotent cells, while fibroblasts specific genes
COL12A1 and COL1A2 were ranked as highly expressed in fibroblasts. Additionally, chroma-
tin related factors such as MBD2, LMNA and H2AFY, previously described to be preferentially
expressed in somatic cells versus pluripotent cells [7,40,41] appeared as highly expressed in
fibroblast (Fig 1A). This result suggests that our method can robustly identify genes that are
differentially expressed between somatic and pluripotent cells.
Among all candidates, we noticed that the protein lysine methyltransferase SETD7 was
highly ranked for upregulated expression in fibroblasts versus pluripotent cells (Fig 1A). Quan-
tification of mRNA levels by qPCR confirmed that SETD7 was clearly up-regulated in keratino-
cytes and fibroblasts compared to iPSCs derived from keratinocytes (KiPSCs) (Fig 1B).
Differences in expression were also confirmed at the protein level (Fig 1C). Also, SETD7 was
expressed at higher levels in in vitro differentiated ESCs compared to ESCs maintained in
undifferentiated conditions both at the mRNA (Fig 1B) and protein level (Fig 1D). Analysis of
ENCODE data (Fig 1E) suggests that the promoter of SETD7 is marked with both H3K4me2/3
and H3K27me3 in the human embryonic stem cell line H1(Fig 1E), a combination of marks
known as bivalent domains [42,43]. Bivalent domains have been suggested to keep differentia-
tion genes poised for activation in pluripotent cells and to resolve into only H3K4me2/3 in
genes that become activated during differentiation [42]. Additionally, RNA polymerase II
(Pol II) was located that the transcriptional start site of SETD7 but no elongation mark
(H3K36me3) was detected at the gene body suggesting that Pol II is poised at the SETD7 pro-
moter and ready for activation in human embryonic stem cells. Last, the presence of a non-
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Fig 1. SETD7 is expressed at very low levels in pluripotent human cells and induced during
differentiation. (A) Average rank of the top 700 most differentially expressed genes between pluripotent
(iPSCs or ESCs) and fibroblasts, including those upregulated in pluripotent cells (left panel) and upregulated
in fibroblasts (right panel). (B) SETD7mRNA levels in human ESCs grown under self-renewal conditions
(UndES[4]), in vitro differentiated human ESCs (DifES[4]), human fibroblasts (HFF), two lines of human
keratinocytes (HEK1 and HEK2) and two lines of iPSCs generated from keratinocytes ([H]KiPS4F and
KiPS4F1). Mean and standard deviation of three technical replicates is shown. Induction of SETD7mRNA
levels during ES[4] differentiation was confirmed in more than four independent differentiation experiments.
(C) Western blot showing SETD7 protein levels in pluripotent and somatic cells. Loading control beta actin
(ACTB) is also shown. (D) Western blot showing protein levels of SETD7, AFP, OCT4 and SOX2 in under
SETD7 Regulates Differentiation
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methylated CpG island is in agreement with the Polycomb complex recruitment to the SETD7
promoter [44,45].
To confirm the presence of bivalent marks and resolution of these marks in somatic cells we
performed chromatin immunoprecipitation (ChIP) in the different cell lines. In agreement
with the differential expression of SETD7 in pluripotent and somatic cells, the regulatory
regions of SETD7 were found to be marked only with H3K4me2 in somatic cells but co-marked
with H3K27me3 in pluripotent cells (Fig 1F). The presence of this bivalency in pluripotent
cells suggests that SETD7 is silent in pluripotent cells but poised for activation during differen-
tiation, similar to other critical developmental regulators [42,43].
SETD7 plays a role in the differentiation of human ESCs
To test if SETD7 has a role in ESCs differentiation, we proceed to knock down the expression of
SETD7 using lentiviral vectors that express shRNAs against SETD7. Five different shRNAs from
SIGMA (MISSION) were tested in 293T and ESCs. Two particular shRNAs (sh28 and sh29)
showed a significant reduction of SETD7mRNA and protein levels both in somatic cells as well
as in in vitro differentiated ESCs (S1A, S1B and S1C Fig). ESCs knocked down for SETD7 by
means of sh28 expression (shSETD7) were differentiated in vitro and levels of pluripotency and
differentiation-related genes were quantified at different days using qPCR. Fig 2A shows that the
silencing of pluripotency-related genesOCT4,NANOG and SOX2 is delayed in SETD7 knock-
down cells compared to cells infected with a control shRNA (shSCR), as well as the induction of
differentiation genes HNF4 and p21. Microarray analysis was performed at different days during
differentiation. Fig 2B shows that genes that are upregulated in the shSETD7 condition compared
to the shSCR at day 8 of differentiation are enriched in pluripotency genes while genes downre-
gulated are mainly differentiation genes, including genes expressed in liver and astroglia. These
results suggest that the SETD7 knock down is affecting both the silencing of pluripotency genes
and the induction of liver specific genes during differentiation. Differentially expressed genes (Fig
2C) included genes of the pluripotency network such as OCT4, SOX2, NANOG, UTF, PRDM14
and TERT among others (S2A Fig) and differentiation genes including HOX genes, apolipopro-
teins, pregnancy specific glycoproteins (expressed in trophectoderm), genes involved in liver
(HNF4A, HMGCS2), muscle (TNNI1), blood (MEIS1, SOX6) and brain differentiation (CBLN2
and KLK6) (S3A Fig). Most differentially expressed genes induced or silenced during differentia-
tion were not significantly affected by the SETD7 knock down in undifferentiated cells (S2C and
S3C Figs) in accordance with the low levels of expression of SETD7 in these cells.
Delayed silencing of the pluripotency-related gene OCT4 was further confirmed at the pro-
tein level by western blot (Fig 3A) and immunohistochemistry (Fig 3B). Additionally, treat-
ment of cells during differentiation with the SETD7 inhibitor PFI-2 [46] at 5μM caused the
sustained expression of OCT4 in a percentage of embryoid bodies compared to the vehicle
(DMSO) treatment (Fig 3C and 3D).
To further confirm the involvement of SETD7 in differentiation we evaluated the cell cycle
distribution of undifferentiated and differentiated ESCs control and knocked down for SETD7.
self-renewing conditions and in vitro differentiated human ESCs. Loading control alpha tubulin (TUBA) is also
shown. One representative experiment out of three is shown. (E) Genomic visualization of the levels of
H3K72me3, H3K4me3, H3K4me2, H3K36me3 and RNA polymerase II (Pol II) in the human embryonic stem
cell line H1 around the SETD7 gene according to ENCODE. A non-methylated CpG island is depicted in
green. (F) Levels of H3K4me2 and H3K27me3 at SETD7 gene promoter region (27 bp upstream of the
transcription start site) in pluripotent and somatic cells determined by chromatin immunoprecipitation (ChIP)
and ploted relative to the input. IgGs wer used as negative control. Bars show the mean and standard
deviation of three independent immunoprecipitations.
doi:10.1371/journal.pone.0149502.g001
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As expected control cells showed a dramatic decrease of cells in S-phase upon differentiation
(Fig 4A and 4B), while cells knocked down for SETD7 showed a significant number of cells in
S phase upon differentiation. These results are consistent with the delays in differentiation
found in SETD7 knock-down cells at the level of gene expression.
Fig 2. The SETD7 knock-down causes a delay in differentiation. (A) mRNA levels of pluripotency factors (OCT4, SOX2, NANOG), differentiation genes
(HNF4 and p21) and SETD7 normalized toGAPDH at different days during the in vitro differentiation of ES[4] transduced with a non target shRNA (shSCR)
and a shRNA (sh28) that targets SETD7 (shSETD7). For pluripotency factors levels were plotted relative to d0 and for differentiation factors levels were
plotted relative to day of maximum expression in the shSCR. Mean and standard deviation from three independent differentiation experiments is shown. (B)
Gene set enrichment analysis (GSEA) of the global changes in gene expression found between shSETD7 and shSCR at day 8 of differentiation. Enrichment
profile, normalized enrichment score (NES), p-value and false discovery rate (FDR) are shown for the significantly enriched gene sets from the Molecular
Signatures Database BENPORATH_ES_1 (genes overexpressed in human embryonic stem cells according to 5 or more out of 20 profiling studies),
HSIAO_LIVER_SPECIFIC_GENES (Liver selective genes), ESC_J1_UP_LATE.V1_UP (Genes up-regulated during late stages of differentiation of
embryoid bodies from J1 embryonic stem cells) and CAHOY_ASTROGLIAL (Genes up-regulated in astroglia cells). (C) Heatmap of the expression of the
400 genes most differentially regulated by shSETD7 KD compared to shSCR and that are upregulated or downregulated more than 16 fold during
differentiation determined by microarray analysis.
doi:10.1371/journal.pone.0149502.g002
SETD7 Regulates Differentiation
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SETD7 binds and methylates histone H1
Accumulating evidence suggests that SETD7 might mediate its physiological effects through
the methylation of proteins different than histone H3 [10,12,25,34,47]. Additionally, the defec-
tive silencing of pluripotency-related genes observed during the differentiation of SETD7
knock-down ESCs can hardly be explained by defects on H3K4me1, since this epigenetic mark
is involved in gene activation. Therefore, we set up to explore other potential methylation tar-
gets that might mediate the physiological role of SETD7 during differentiation.
Fig 3. The SETD7 knock-down causes defects in the silencing of pluripotency genes. (A) Western blot
showing the levels of OCT4 at different days during the in vitro differentiation of ES[4] transduced with a non
target shRNA (shSCR) and a shRNA that targets SETD7 (shSETD7) (B) Immunolocalization of SOX2
(green) and OCT4 (red) expression at day 4 and day 15 of in vitro differentiation of ES[4] transduced with a
non target shRNA (shSCR) and a shRNA that targets SETD7 (shSETD7) (C) Quantification of the
percentage of embryoid bodies negative or positive for OCT4 staining at day 4 and day 7 of differentiation of
cells treated with vehicle (DMSO), 1μM or 5μMPFI-2. (D) Immunolocalization of OCT4 (red) in embryoid
bodies at day 4 and day 7 of in vitro differentiation of ES[4] treated with vehicle (DMSO) or 5μMPFI-2.
doi:10.1371/journal.pone.0149502.g003
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Since SETD7 is expressed mostly in differentiated cells we hypothesized that the methyla-
tion target through which SETD7 might be influencing the differentiation of pluripotent cells
is likely to be expressed in differentiated cells. In order to identify potential targets of SETD7
in differentiated cells we analyzed SETD7 interacting proteins by mass spectrometry in HeLa
cells (Fig 5A). For that, FLAG tagged SETD7 was overexpressed in HeLa cells (Fig 5B). Overex-
pression did not change localization of SETD7 in HeLa cells (S1D Fig). Soluble nuclear extracts
Fig 4. The SETD7 knock-down affects the cell cycle profile of differentiating cells. (A) Cell cycle profile of undifferentiated and after 15 days of in vitro
differentiation of ES[4] transduced with a non target shRNA (shSCR) and a shRNA that targets SETD7 (shSETD7). (B) Mean of the percentage of cells in
each phase of the cell cycle in three independent differentiation experiments. *Differences in the percentage of cells in S-phase between shSETD7 and
shSCR in differentiated cells was found significant at a p-value<0.05.
doi:10.1371/journal.pone.0149502.g004
Fig 5. Analysis of SETD7 interacting proteins. (A) Strategy for the purification of interacting proteins. (B)
Levels of endogenous and overexpressed SETD7 in infected HeLa cells infected with pWPI-FLAG (FLAG) or
pWPI-FLAG:SETD7 (FLAG:SETD7) determined by western blot. (C) Coomassie blue staining of the
immunoprecipitated proteins. Molecular weight markers, anti FLAG-immunoprecipitated proteins from cells
transduced with empty vector and cells transduced with FLAG:SETD7 expressing vector are shown.
doi:10.1371/journal.pone.0149502.g005
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were prepared and FLAG:SETD7 was immunoprecipitated using anti FLAG antibodies. Two
independent immunoprecipitations were carried out in which the immunoprecipitated mate-
rial was resolved in a SDS-polyacrylamide gel and subjected to in gel digestion (Fig 4C) or
digested in solution for further analysis by mass spectrometry. Table 1 shows the number of
spectral counts for proteins that were significantly enriched in the anti-FLAG:SETD7 immuno-
precipitation compared to the control (cells infected with pWPI:FLAG). Interacting proteins
were mainly enriched in RNA splicing (p-value: 2.3 E-9) and gene expression (p-value: 6.2E-4)
categories.
Among interacting proteins we noticed the presence of linker histone H1.2 (HIST1H1C)
that has prominent roles in the regulation of chromatin structure and gene expression. The
interaction of SETD7 with H1.2 suggested that linker histone H1 could be a target for SETD7-
mediated methylation. In accordance, we found that the treatment of HeLa cells with 5μM
PFI-2 reduced the levels of methylation of the histone fraction (including H1 variants) com-
pared to cells treated with vehicle (S4 Fig).
To confirm the methylation of H1 variants by SETD7 we conducted in vitromethylation
assays. SETD7 was able to methylate full length recombinant histone H3 and histone H3 tail
Table 1. SETD7 interacting proteins identified by mass spectrometry.
In gel In Solution
FLAG F:SETD7 FLAG F:SETD7
SETD7 9 123 0 255 Bait
PHF5A 0 2 0 1
HNRNPF 0 1 0 11
PTBP1 0 1 1 5
SRRM2 0 1 1 7
SNRPB 0 6 0 1 Splicing/RNA procesing
SF3B4 0 2 0 1
SFRS1 0 2 0 2
SFRS3 0 5 0 2
TRA2B 0 1 0 2
FBL 2 12 0 3
LUC7L2 0 2 0 4
SRP14 0 10 0 2
CAPRIN1 0 1 0 1
HIST1H1C 0 7 0 2
GATAD2B 0 2 0 1
LMNA 0 1 4 30
DEK 0 1 0 1 Transcription/Nuclear organization
RUVBL1 0 3 0 1
PRKDC 5 114 8 21
RIF1 0 1 1 4
PCNA 0 5 0 1
EEF1D 0 12 0 8
PSMC1 0 4 0 1 Others
PHGDH 0 3 1 2
PFKFB2 3 20 0 8
The table shows the number of total peptide spectra matched to the indicated proteins per condition.
doi:10.1371/journal.pone.0149502.t001
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(Fig 6A), as previously described. SETD7 was also able to methylate a preparation of linker his-
tones from calf thymus, while the arginine methyltransferase PRMT1 was unable to do so. We
next confirmed that SETD7 was able to methylate all the tested recombinant H1 histone vari-
ants (Fig 6A, right panel). Among them, two particular variants were selected for follow up;
H1.4 because it showed a high methylation activity despite the low levels of protein assayed
and H1.0 because it has been previously suggested to play a role in human ESCs differentiation
[48]. In vitromethylation assays using deletions and point mutations in recombinant H1.0
revealed that the main methylation site was located at K17 in the N-terminal domain (Fig 6B,
left panel) which was confirmed by mass spectrometry (Table 2). Histone H1.4 was found to be
methylated at K129 in the C-terminal domain since mutations at this site dramatically affected
the levels of methylation (Fig 6B, right panel). Mass spectrometry data (Table 2) confirmed this
methylation site and revealed the presence of an additional methylation site in the N-terminal
domain at K34.
Methylation of H1.4 by SETD7 causes conformational changes
In order to understand the biological function of H1 methylation by SETD7 we tested if meth-
ylation of H1.4 could be causing conformational changes. Therefore, we analyzed the effect of
methylation by SETD7 in the secondary structure of H1.4 in solution and bound to DNA by
FTIR. In aqueous solution the methylated protein (4 methyl groups incorporated on average,
see S5A Fig) showed no significant changes when compared to unmethylated H1.4 (S5B and
S5C Fig). However, differences in the amount of secondary structure were observed upon
DNA binding. In the complexes the percentages of α-helix increased from 20% to 27% in the
unmethylated protein, while those of β-structure only had a slight increase from 22% to 26% in
the presence of DNA. The opposite was true for the complexes with methylated H1.4 where
the greatest increase was in β-structure from 25% to 33%, while the amount of α-helix
remained almost unchanged (S5B and S5C Fig). In conclusion, H1.4 methylated by SETD7,
upon binding to DNA, tended to form less α-helix but more β-structure than unmethylated
H1.4.
SETD7 regulates the incorporation of histone H1 during differentiation
We have previously reported that histone H1 is incorporated into the regulatory regions of
pluripotency genes to mediate their silencing during the differentiation of human ESCs [48].
Therefore we set up to quantify if the silencing of SETD7 expression could be affecting the
incorporation of linker H1 to these regions during differentiation. Chromatin immunoprecipi-
tation experiments confirmed that H1 incorporation to the pluripotency-related genes OCT4
and NANOG during differentiation is lower in SETD7 knock-down cells, suggesting that H1
methylation by SETD7 could contribute to the recruitment of H1 to pluripotency genes during
differentiation and their silencing (Fig 6C). Importantly, the expression levels of H1 variants
were not significantly affected by the shSETD7 during differentiation (S3C Fig).
Discussion
Growing evidence suggests that not only classical transcription factors are induced during dif-
ferentiation to orchestrate the expression of tissue specific programs. Important chromatin reg-
ulators are also developmentally regulated and contribute to regulate the expression of the
appropriate set of genes in differentiated cells. Here, we show that SETD7 is strongly upregu-
lated during the differentiation of human pluripotent cells and differentially expressed between
iPSCs and somatic cells. Furthermore, although the role of bivalent domains in repressing
developmental genes in ESCs remains controversial [49], the fact that SETD7 is marked with
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Fig 6. SETD7methylates linker histone H1 and affects its recruitment to chromatin during differentiation. (A) In vitromethylation reactions showing
the activity of SETD7 and PRMT1 on histones H3 and H1. Coomassie blue staining of SDS-PAGE gels (upper panel) and autoradiography (lower panel) of
four different gels are shown. (B) In vitromethylation reactions mapping the methylation sites of linker histones H1.0 and H1.4 by SETD7. Coomassie blue
staining of SDS-PAGE gels (upper panel) and autoradiography (lower panel) of three different gels are shown. Arrows show the expected molecular weight
of the recombinant proteins. (C) Chromatin immunoprecipitation showing the recruitment of total H1 to two regions of the OCT4 promoter at 15 days of in vitro
differentiation of ES[4] transduced with a non target shRNA (shSCR) and a shRNA that targets SETD7 (shSETD7). Positions indicate Kb from the
transcription start site. Levels were normalized to the input and plotted relative to a negative control region in theGAPDH gene promoter. Mean and standard
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bivalent domains in pluripotent cells further suggests that it is an early important developmen-
tal regulator.
Our results raise the possibility that methylation of histone H1 by SETD7 could be involved
in the regulation of ESCs differentiation. All tested H1 variants were found to be methylated by
SETD7 in vitro, including H1.2 that was identified as a SETD7 interacting protein in the immu-
noprecipitation experiments. Further analysis of methylation sites revealed that histone H1.4
was found to be methylated in vitro by SETD7 at K129 in the C-terminal domain and at K34 in
the N-terminal domain. Our report is consistent with a recent paper that describes methylation
of H1.4 at several lysines on the C-terminal domain [50]. Moreover, our work shows that K129
is the key residue for SETD7 driven methylation, since its mutation greatly reduces methylation
levels in vitro. Despite this fact, mass spectrometry data showed prominent levels of K34 meth-
ylation when analyzing the wild type recombinant H1.4. Interestingly, H1.4 K34 has been
found to be acetylated and methylated in vivo [51,52]. Acetylation of K34 increases H1.4
mobility and it is particularly prominent in pluripotent cells [51], likely contributing to the
hyperdynamic binding of linker histones to chromatin in these cells [53]. We hypothesize that
the induction of SETD7 during differentiation will lead to methylation of H1.4 at K34 and
therefore reduce the levels of acetylation by competition, contributing to the establishment of
the proper heterochromatin patterns during differentiation. Additionally, K34 of H1.4 is con-
served in H1.2 and H1.3 variants which have been previously found to be methylated, acety-
lated and formylated at this residue in mouse tissues [52]. These data suggests that the target
sites of SETD7 methylation in H1 histones might be subject of intense regulation by posttran-
scriptional modifications.
Upon methylation by SETD7, differences in the percentages of secondary structure of H1.4
when bound to DNA were observed, suggesting DNA-dependent conformational changes in
H1.4. Those changes are presumably due to a different folding of H1 terminal domains
deviation of three independent differentiation experiments is shown. (D) As in C but testing two regions of the NANOG promoter (E) Reported SETD7
methylation targets.
doi:10.1371/journal.pone.0149502.g006
Table 2. Residuesmodified by SETD7 in H1.0 and H1.4 found bymass spectrometry.
Histone Methylated K # modiﬁed peptides
H1.0 K12 4
K14 3
K17 42
K20 13
K17&K20 10
K21 5
K20&K21 1
K27 1
K111 1
H1.4 K34 21
K127 9
K129 21
K130 3
The table shows the number of modiﬁed peptides containing the indicated modiﬁcations after the analysis
of in vitro methylated H1.0 (construct 1–116 aa) or H1.4 (construct 1–135) by mass spectrometry.
doi:10.1371/journal.pone.0149502.t002
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determined by the incorporation of methyl groups. Conformational changes associated with
posttranslational modifications and characterized by an increase in β-structure at the C-termi-
nal domain were previously described for H1 bound to DNA and in chromatin [54,55]. Recog-
nition of methylated positions in H3 by several chromatin readers, including HP1, are
mediated by β-sheet protein−protein interactions [56,57], so conformational changes induced
by H1 methylation could affect interactions with consequences on chromatin organization or
compaction. Alternatively, H1 methylation by SETD7 may influence its turnover or exchange.
We have previously reported a role for histone H1 in the silencing of pluripotency-related
genes during the differentiation of human embryonic stem cells [48]. Differentiation entails
changes in total H1 content, as well as changes in the relative levels of H1 variants. Most prom-
inent change is the induction of H1.0 variant and recruitment to pluripotency-related genes to
facilitate their silencing. Here, we propose that the induction of SETD7 expression might be
also contributing to the recruitment of H1 to those genes during differentiation.
Due to the complexity of the differentiation process and the multiple targets that have been
proposed for SETD7 (Fig 5E) a more systematic approach will be needed in the future to dissect
the specific effects of SETD7 on H1 biology. For example, raising specific antibodies against
methylated H1 to investigate how and where methylated H1 is incorporated into chromatin
during differentiation would be of interest. Additionally, performing mass spectrometry to
compare the modification patterns of H1 in differentiated and undifferentiated cells could be
appropriate. Moreover, our co-immunoprecipitation analysis suggest that additional proteins
might interact and be potentially methylated by SETD7 or regulate SETD7 activity. We have
shown here the common interactors found in two independent immunoprecipitations. How-
ever, since co-immunoprecipitation is not exempt from artifacts and false positives, additional
experiments will be needed to carefully verify the specificity of these interactors.
Since SETD7 is able to methylate multiple targets one might anticipate widespread effects
upon differentiation. Accordingly, a report published during the preparation of this manu-
script suggests that SETD7 can contribute to the differentiation of ESCs by methylating and
regulating the stability of the pluripotency factor SOX2 [58]. Eventually, methylation of other
targets such as YAP or LIN28A could be potentially involved in the effects of SETD7 in differ-
entiation [59–61]. Although most of the current effort in the field has been dedicated to the
characterization of changes in the transcriptome during differentiation, regulation of protein
translation is also emerging as a key regulatory mechanism [62]. Additionally, we suggest that
differential expression of protein modifying enzymes could be contributing to the establish-
ment of posttranslational modifications that play a key role in differentiation. Therefore, a
closer look at the proteome and its modifications appears critical to fully understand the
molecular events involved in differentiation.
Conclusions
We show that SETD7 is expressed at very low levels in human ESCs and induced during differ-
entiation. Knock-down of SETD7 causes differentiation defects in human embryonic stem
cells. SETD7 methylates linker histone H1 in vitro causing conformational changes in H1.
These effects correlate with a decrease in the recruitment of H1 to the pluripotency genes
OCT4 and NANOG during differentiation in SETD7 knocked down cells, which might affect
the proper silencing of these genes during differentiation.
Supporting Information
S1 Fig. Knock down efficiency of different shRNAs against SETD7. (A) Levels of SETD7
mRNA normalized to GAPDH in undifferentiated ES[4] (UndES[4]), in vitro differentiated ES
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[4] for 15 days (DifES[4]) and 293T cells transduced with a non target shRNA (shSCR) and 5
different shRNAs against SETD7 (shSETD7). (B) Western blot showing the protein levels of
SETD7 in 293T cells transduced with a non target shRNA (shSCR) and 5 different shRNAs
against SETD7 (shSETD7). (C) Western blot showing the protein levels of SETD7 in undiffer-
entiated ES[4] (UndES[4]) and in vitro differentiated ES[4] for 15 days (DifES[4]) cells trans-
duced with a non target shRNA (shSCR) and 5 different shRNAs against SETD7. (D)
Subcellular distribution of SETD7 in Hela cells infected with pWPI-FLAG and pWPI-FLAG:
SETD7. Cytoplasmic and nuclear fractions are shown. Immunoblot of transcription factor AP-
2 shows the enrichment of nuclear proteins in the nuclear vs. cytoplasmic fractions.
(PDF)
S2 Fig. Expression of genes downregulated during differentiation affected by the shSETD7.
(A) mRNA levels of different pluripotency-related genes during differentiation in the shSCR
(full lines) and the shSETD7 (dotted lines) cell lines. (B) Blox plot of the levels of expression of
the upregulated genes depicted in Fig 2C and p-values of the differential expression between
the indicated categories according to t-test (C) Levels of expression of housekeeping genes dur-
ing differentiation.
(PDF)
S3 Fig. Expression of genes upregulated during differentiation affected by the shSETD7.
(A) mRNA levels of several differentiation genes during differentiation in the shSCR (full lines)
and the shSETD7 (dotted lines) cell lines. (B) Blox plot of the levels of expression of the down-
regulated genes depicted in Fig 2C and p-values of the differential expression between the indi-
cated categories according to t-test (C) Heatmap of the levels of expression of H1 variants
during differentiation of the shSCR and the shSETD7 cell lines.
(PDF)
S4 Fig. Effects of the PFI-2 and Adox inhibitors in the methylation of the histone fraction.
HeLa cells were labeled with [methyl-3H]-L-methionine for 3 h in the presence of protein-syn-
thesis inhibitors, and in the presence of vehicle or the SETD7 inhibitor PFI-2 (5 μM) or the
general methyltransferase inhibitor AdOx (20 μM). Acid extraction of histone fraction was per-
formed and proteins resolved by SDS-PAGE, visualized by Coomassie blue staining, followed
by autoradiography. Western blot with anti H1.0 antibody is shown as loading control. () Cor-
responds to methylated H1 bands.
(PDF)
S5 Fig. Effect of methylation by SETD7 in the seconday structure of H1.4 in solution and
bound to DNA. (A) Effect of methylation by SETD7 in the seconday structure of H1.4 in solu-
tion and bound to DNA. A, Mass spectrometry spectra of in vitro methylated H1.4 with 4
methyl groups incorporated on average, compared to unmethylated protein. (B) Infrared spec-
troscopy results for the unmethylated and methylated proteins in solution and bound to DNA.
(C) Amide I decomposition of the unmethylated and methylated H1.4 in solution and bound
to DNA. The α-helix component is highlighted in orange and the β-structure component is
highlighted in light blue. Infrared measurements were performed at a protein concentration of
5 mg/ml in 10mMHepes pH 7.0, plus 140 mMNaCl as described in Experimental Procedures.
The protein/DNA ratio (r) (w/w) was 0.7.
(PDF)
S1 Table. Ranking of the top 700 most differentially expressed genes between pluripotent
cells (iPSCs and ESCs) and fibroblast.
(XLS)
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S2 Table. Expression (Log2) of the top 400 most differentially expressed genes between
shSCR and shSETD7 induced (UP) or repressed (DOWN) during differentiation.
(XLS)
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